Home > Boards > US OTC > Biotechs > Biostage Inc. (BSTG)

I don't remember the company telling us about this:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
AKthisistheone Member Profile
 
Followed By 20
Posts 3,643
Boards Moderated 2
Alias Born 05/21/15
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2019 4:05:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 8:01:26 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/13/2019 5:27:10 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/13/2019 5:26:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 6:07:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2019 4:08:40 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/11/2019 4:12:39 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/11/2019 4:08:38 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/1/2019 4:33:53 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2019 5:00:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/28/2019 5:15:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/20/2019 5:15:39 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 2/20/2019 5:14:22 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/4/2019 4:17:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/21/2018 4:51:11 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/21/2018 4:49:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/16/2018 5:28:13 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/16/2018 5:14:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2018 4:07:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2018 8:32:15 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/8/2018 7:31:56 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2018 4:27:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2018 7:11:30 AM
Withdrawal of Registration Statement (rw) Edgar (US Regulatory) - 8/10/2018 4:18:08 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 7/11/2018 4:07:36 PM
AKthisistheone   Friday, 12/15/17 08:21:57 PM
Re: None
Post # of 1218 
I don't remember the company telling us about this:


On April 14, 2017, representatives for the estate of a deceased individual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company, Harvard Bioscience and other defendants. The complaint alleges that the decedent was harmed by two tracheal implants that incorporated synthetic trachea scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in two surgeries performed in 2012 and 2013, which harm caused her injury and death. The civil complaint seeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuit relates to the Company’s first generation trachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Cellframe technology nor to its lead development product candidate, the Cellspan esophageal implant. The litigation is at an early stage and the Company intends to vigorously defend this case. While the Company believes that such claim lacks merit, and has filed a motion seeking dismissal of the lawsuit, the Company is unable to predict the ultimate outcome of such litigation. In accordance with a separation and distribution agreement between Harvard Bioscience and the Company relating to the Separation, the Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer as a result of this litigation. The Company has been informed by its insurance provider that the case has been accepted as an insurable claim under the Company’s product liability insurance policy.

“Better to do something imperfectly than to do nothing flawlessly."
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist